Literature DB >> 21391473

Performance evaluation of the new rapid fertility assays in whole blood and plasma on PATHFAST.

Yuuko Sugie1, Ko Igami, Keiichi Shoji, Nozomi Arai, Yukiko Tazaki, Hideki Kouta, Yoshikazu Okamura, Shigeru Tashiro, Hiroyuki Yokoi.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the validity of the PATHFAST fertility marker assays for the rapid measurement of female hormones including: LH, FSH, Estradiol (E2), Progesterone (P4), Prolactin (PRL), and HCG. As for the PATHFAST fertility marker assays, female hormones can be measured by whole blood, plasma, and serum.
METHODS: The correlation of the heparin whole blood and the plasma samples in the PATHFAST was examined. The method comparison study of PATHFAST fertility marker assays was performed with the Elecsys 2010, AIA-360, IMMULITE 2000, miniVIDAS, and ARCHITECT i2000. Determination of the reference range values of the PATHFAST fertility marker assays was performed with serum samples which were obtained during the follicular phase, mid-cycle, luteal phase, and postmenopausal phase.
RESULTS: The results of plasma samples of female hormones measured by the PATHFAST correlated highly with those of whole blood samples (r > 0.9). The results of LH, FSH, E2, P4, PRL, and HCG as measured by the PATHFAST correlated well with other commercial fertility assays (r > 0.9). Reference values of PATHFAST fertility marker assays were equivalent to those of other commercial methods.
CONCLUSIONS: The PATHFAST system is an accurate diagnostic tool for the rapid assay of female hormones. The PATHFAST fertility marker assays can be useful in a physician's office laboratory (POL) as well as various clinical sites during infertility treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21391473

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  5 in total

1.  Pathfast presepsin assay for early diagnosis of systemic inflammatory response syndrome in patients with nephrolithiasis.

Authors:  Yan-song Hou; Hua Wang; Hao Chen; Ling-feng Wu; Lin-feng Lu; Yi He
Journal:  Biomed Res Int       Date:  2015-02-04       Impact factor: 3.411

2.  Evaluation of the chemiluminescent enzyme immunoassay system for the measurement of testosterone in the serum and whole blood of stallions.

Authors:  Yuko Toishi; Nobuo Tsunoda; Shun-Ichi Nagata; Rikio Kirisawa; Kentaro Nagaoka; Gen Watanabe; Yojiro Yanagawa; Seiji Katagiri; Kazuyoshi Taya
Journal:  J Reprod Dev       Date:  2017-11-11       Impact factor: 2.214

3.  Evaluation of the PATHFAST Chemiluminescent Enzyme Immunoassay for Measuring Progesterone in Whole Blood and Serum of Mares.

Authors:  Yuko Toishi; Nobuo Tsunoda; Masaaki Tagami; Hiromitsu Hashimoto; Fumiki Kato; Tsukasa Suzuki; Kentaro Nagaoka; Gen Watanabe; Shota Tokuyama; Kiyoshi Okuda; Kazuyoshi Taya
Journal:  J Equine Sci       Date:  2013-09-30

4.  Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment.

Authors:  Michael Behnes; Thomas Bertsch; Dominic Lepiorz; Siegfried Lang; Frederik Trinkmann; Martina Brueckmann; Martin Borggrefe; Ursula Hoffmann
Journal:  Crit Care       Date:  2014-09-05       Impact factor: 9.097

5.  PATHFAST, a novel chemiluminescent enzyme immunoassay for measuring estradiol in equine whole blood and serum.

Authors:  Yuko Toishi; Nobuo Tsunoda; Kouiti Kume; Kentaro Nagaoka; Gen Watanabe; Kazuyoshi Taya
Journal:  J Reprod Dev       Date:  2016-08-20       Impact factor: 2.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.